The Revenue Math of Patient Persistence

Why the 90% matters more than you think — and why most pharma is investing in the wrong part of the journey.

A CCO at a specialty pharma company said something at a dinner recently that's stayed with me.

"We're hitting all our activation metrics. Enrollment is up. First fill is strong. But our two-year persistence keeps eroding. And nobody at the board table wants to hear that we don't know why."

Strong activation. Declining persistence. No clear connection between the two.

It's not an operational problem. It's a revenue problem.

And most pharma is investing in the wrong part of the journey to solve it.

Where the Revenue Actually Lives

Pharma economics on specialty therapies follow a pattern most senior commercial leaders recognize.

The first 90 days of a patient journey concentrate on activation — enrollment, benefit verification, first fill. This is where most patient support budgets, vendor capabilities, and operational attention focus.

The next 18-24 months are about persistence — daily adherence, side effect management, coverage transitions, refill coordination. This is where therapeutic continuity is actually decided.

But the revenue math runs in the opposite direction of where the budgets sit.

Year 1 revenue per patient is meaningful. Year 2 revenue compounds. Year 3 revenue is where lifetime value accumulates.

Consider an illustrative scenario: a specialty therapy priced at $100,000 annually. If persistence declines steeply year over year — strong in Year 1, weaker in Year 2, weaker still in Year 3 — lifetime value per patient lands well below the program's potential.

If that same therapy holds even modestly stronger persistence across the three years — a few percentage points higher each year — lifetime value per patient rises significantly. Across a 1,000-patient population, the cumulative revenue difference can reach tens of millions over three years.

The math isn't precise without your specific portfolio data. But the direction is consistent: small improvements in Year 2 and Year 3 persistence produce outsized returns on lifetime value — and that compounding is where the revenue actually lives.

Why Activation Spending Hits a Ceiling

Most pharma teams have already optimized activation.

Hubs hit their SLAs. Specialty pharmacies fill on time. Foundation applications process efficiently. Benefit verification is fast.

There's diminishing marginal return in spending more on the 10%.

The 90% — the daily decisions, the coverage transitions, the side-effect navigation that happens between visits — is where every additional dollar of investment carries higher marginal value.

But this is also where most pharma has the least visibility, the least infrastructure, and the least accountability across functions.

The result: budgets concentrate where returns have plateaued, and the part of the journey that actually drives revenue compounding remains underfunded.

What CCOs Are Starting to Ask

The senior commercial leaders who recognize this pattern are no longer asking "How do we improve patient engagement?"

They're asking sharper questions:

Where in the patient journey is our revenue actually leaking?

What's the lifetime value impact of improving persistence by even a few percentage points?

Why are we still concentrating budget on the part of the journey that's already working?

What infrastructure would shift that allocation — and what would it cost to build?

These questions don't get answered by operational consultants or vendor scorecards.

They get answered by mapping where persistence actually leaks and quantifying what each gap is costing.

The Strategic Shift

The companies that will lead specialty pharma over the next three years aren't the ones with the best activation programs.

They're the ones that recognize patient persistence is a revenue strategy, not an operational metric — and build the infrastructure to act on it.

This is the work we're refining with senior commercial leaders right now: a structured way to identify where revenue is leaking across the 90% and prioritize the infrastructure investments that move the persistence math.

If your team is asking these questions but can't quite see where the revenue is going, send me a message.

— Liza, Linked Patient Learning